---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022575"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:20:08.159799+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves BriaCell's registrational study design for Bria-IMT combo in advanced breast cancer

## Summary
- FDA approved primary and secondary endpoints, study design, and patient population for Bria-IMT plus checkpoint inhibitor in advanced metastatic breast cancer.
- Trial is randomized, open-label with three arms: Bria-IMT combo, physician's choice, and Bria-IMT alone.
- Patients must have exhausted all other treatment options; recruitment and dosing begin summer 2023.
- Upon statistically significant milestones, BriaCell may apply for full approval via BLA filing.
- CEO notes FDA's route to accelerate development for difficult-to-treat patient population.

## SEC filing metadata
- accession: 0001493152-23-022575
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223022575/0001493152-23-022575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223022575/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022575
- JSON: https://secwatch.observer/filing/0001493152-23-022575.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.